HC Wainwright reaffirmed their buy rating on shares of Prothena (NASDAQ:PRTA - Free Report) in a research report report published on Friday,Benzinga reports. The brokerage currently has a $48.00 price objective on the biotechnology company's stock. HC Wainwright also issued estimates for Prothena's Q4 2025 earnings at ($0.58) EPS.
Other research analysts also recently issued reports about the company. StockNews.com downgraded Prothena from a "hold" rating to a "sell" rating in a report on Tuesday, November 19th. Chardan Capital restated a "buy" rating and set a $40.00 target price on shares of Prothena in a report on Friday. Oppenheimer lifted their price target on Prothena from $58.00 to $62.00 and gave the company an "outperform" rating in a report on Friday, February 7th. Finally, Bank of America decreased their price objective on shares of Prothena from $26.00 to $22.00 and set a "neutral" rating on the stock in a report on Thursday, December 19th. Three analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $45.83.
Check Out Our Latest Analysis on PRTA
Prothena Stock Down 3.9 %
NASDAQ:PRTA traded down $0.60 during trading hours on Friday, reaching $14.63. The company had a trading volume of 387,703 shares, compared to its average volume of 376,842. The stock has a 50-day moving average of $14.38 and a two-hundred day moving average of $16.73. Prothena has a one year low of $11.70 and a one year high of $31.03. The firm has a market capitalization of $787.23 million, a PE ratio of -6.36 and a beta of 0.08.
Prothena (NASDAQ:PRTA - Get Free Report) last posted its earnings results on Thursday, February 20th. The biotechnology company reported ($1.08) earnings per share for the quarter, missing the consensus estimate of ($1.02) by ($0.06). Prothena had a negative return on equity of 22.67% and a negative net margin of 90.50%. The firm had revenue of $2.12 million during the quarter, compared to the consensus estimate of $7.53 million. As a group, sell-side analysts expect that Prothena will post -4.04 earnings per share for the current year.
Institutional Trading of Prothena
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Wellington Management Group LLP lifted its position in Prothena by 22.8% during the 4th quarter. Wellington Management Group LLP now owns 5,130,876 shares of the biotechnology company's stock valued at $71,063,000 after purchasing an additional 952,088 shares during the period. Boxer Capital Management LLC bought a new stake in shares of Prothena during the fourth quarter worth approximately $9,556,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in Prothena by 1,122.9% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 526,748 shares of the biotechnology company's stock valued at $8,812,000 after buying an additional 483,673 shares during the period. Federated Hermes Inc. boosted its stake in Prothena by 84.3% in the fourth quarter. Federated Hermes Inc. now owns 746,177 shares of the biotechnology company's stock valued at $10,335,000 after acquiring an additional 341,274 shares during the last quarter. Finally, Finepoint Capital LP grew its holdings in Prothena by 51.6% during the 4th quarter. Finepoint Capital LP now owns 657,071 shares of the biotechnology company's stock worth $9,100,000 after acquiring an additional 223,600 shares during the period. 97.08% of the stock is currently owned by institutional investors and hedge funds.
Prothena Company Profile
(
Get Free Report)
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease.
See Also
Before you consider Prothena, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Prothena wasn't on the list.
While Prothena currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
